

**Prevalence of Chlamydia pneumoniae-specific Ig G among  
primigravidae and the impact of anti-chlamydia treatment  
on the development of pre-eclampsia**

**A thesis**

**Submitted for Partial Fulfillment of M.D. Degree in Obstetrics  
and Gynecology**

**BY**

***Adel Shafik Salah El Din***

**Assistant lecturer of obstetrics and gynecology**

**Ain Shams University Hospital**

**M.B., B.CH. (1999), M. Sc. (2004).**

**UNDER SUPERVISION OF**

***Professor Mahmoud Ali Ahmed El Shourbagy***

**Professor of Obstetrics and Gynecology**

**Ain Shams University**

***Professor Mohammad Abdel Sabour Faramawy***

**Professor of Chest diseases**

**Ain Shams University**

***Professor Khalid Kamal Ali Sayed***

**Professor of Obstetrics and Gynecology**

**Ain Shams University**

***Assistant Professor Maha Mohammad Fathy***

**Assistant Professor of Microbiology and Immunology**

**Ain Shams University**

***Doctor Karim Ahmed Hassan Wahba***

**Lecturer in Obstetrics and Gynecology**

**Ain Shams University**

**Faculty of Medicine**

**Ain Shams University**

**2008**

## *Acknowledgement*

*First and foremost, I Thank **Allah** who granted me the strength to accomplish this work,*

*Words do fail to express my deepest gratitude and appreciation to **Prof. Dr. Mahmoud Ali Ahmad El-Shourbagy**, Professor of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, for his generous supervision, keen interest, excellent guidance and powerful support. I really consider myself very fortunate that I worked under his generous supervision.*

*Words can never express my deep gratitude and sincere consideration to **Dr. Mohammad Abdel Sabour Faramawy**, Professor of chest diseases, Faculty of Medicine, Ain Shams University, for his valuable instructions and meticulous advices.*

*My deepest thanks and appreciation go to **Prof. Dr. Khalid Kamal Ali Sayed**, Professor of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, for his valuable instructions, kind support, meticulous advices and expert touches.*

*I would like to express my deepest thanks and sincere gratitude to **Dr. Karim Ahmed Hassan Wahba**, Lecturer in Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, for his continuous guidance and instructions. His effort is most truly appreciated. Without his keen guidance, it would have never been possible to accomplish this work,*

*I would like to sincerely thank **Dr. Maha Mohammad Fathy**, Assistant Professor of Microbiology & Immunology, Faculty of Medicine, Ain Shams University, who offered a grateful help in the practical part of the study.*

*I would like to sincerely thank all my Professors and Colleagues in the Obstetrics and Gynecology Department, for the support and overwhelming care with which they surrounded me.*

*I would also like to truly thank each and every person who gave me a hand in accomplishing this work especially my kind subjects who were so cooperative till the end of the study.*

*Last but not least, my true affection and love goes to all my family members, who were, and will always be, by my side and without whom I would have never been able to accomplish this work. Their love, patience and support are most appreciated.*

*Adel Shafik Salah El-Din*

## List of Contents

Title	Page
<i>List of abbreviations</i> .....	
<i>List of tables</i> .....	
<i>List of figures</i> .....	
• <b>Introduction</b> .....	1
• <b>Aim of the Work</b> .....	4
• <b>Review of literature:</b>	
- Chlamydia .....	5
- Preeclampsia.....	26
- The postulated role of Chlamydia pneumoniae in the pathogenesis of preeclampsia.....	41
• <b>Patients and Methods</b> .....	72
• <b>Results</b> .....	80
• <b>Discussion</b> .....	116
• <b>Summary</b> .....	127
• <b>Conclusion and Recommendations</b> .....	130
• <b>References</b> .....	131
• <b>Arabic Summary</b> .....	--

## List of Abbreviations

<b>ACS</b>	Acute Coronary Syndrome
<b>ADMA</b>	Asymmetric dimethyl arginine
<b>ANG-II</b>	Angiotensin II
<b>ASM</b>	American Society of Microbiology
<b>AT-1 AA</b>	Angiotensin II Type 1 Receptor Agonistic Autoantibodies
<b>ATP</b>	Adenosine triphosphate
<b>AZACS</b>	AZithromycin in Acute Coronary Syndromes
<b>BAL</b>	Broncho-aveolar lavage
<b>bFGF</b>	basic fibroblast growth factor
<b>BGMK</b>	Buffalo Green Monkey Kidney cells
<b>BMI</b>	Body Mass Index
<b>BP</b>	Blood pressure
<b>C.pneumoniae</b>	Chlamydia pneumoniae
<b>CABG</b>	Coronary Artery Bypass Grafting
<b>CAD</b>	Coronary artery disease
<b>CDC</b>	Centre for Disease Control
<b>CF</b>	Complement fixation
<b>Cgmp</b>	Cyclic guanosine monophosphate
<b>Chsp</b>	Chlamydial heat shock protein
<b>CMI</b>	Cell mediated immunity
<b>CNS</b>	Central Nervous System
<b>COPD</b>	Chronic Obstructive Pulmonary Disease
<b>Cpn IgG</b>	Chlamydia pneumonia Immunoglobulin G
<b>CRP</b>	C-reactive protein
<b>DIC</b>	Disseminated intravascular coagulation
<b>DNA</b>	Deoxyribonucleic acid
<b>EB</b>	Elementary body
<b>ECE</b>	Endothelin converting enzyme
<b>EDHF</b>	Endothelial derived hyperpolarizing factor
<b>EGF</b>	Epidermal Growth Factor
<b>EIA</b>	Enzyme immune-assay
<b>ELISA</b>	Enzyme-linked immunosorbent assay
<b>EM</b>	Electron microscopy
<b>FITC</b>	Fluorescence thiocyanate
<b>FMD</b>	Flow-mediated dilation



## List of Abbreviations (Cont.)

<b>GIT</b>	GastroIntestinal Tract
<b>HDL</b>	High Density Lipoprotein
<b>Hela cells</b>	Human Cervical Carcinoma Cells
<b>HELLP</b>	Hemolysis, Elevated Liver enzymes and Low Platelets
<b>HIV</b>	Human immunodeficiency virus
<b>HLA</b>	Human leukocyte antigen
<b>NICU</b>	Neonatal intensive care unit
<b>NK</b>	Natural killer cells
<b>NKB</b>	Neurokinin-B
<b>NO</b>	Nitric oxide
<b>NOS</b>	Nitric oxide synthetase
<b>nPCR</b>	nested Polymerase chain reaction
<b>NRBCs</b>	Nucleated Red Blood Cells
<b>PAF</b>	Platelet Activating Factor
<b>PAI</b>	Plasminogen Activator Inhibitor
<b>PBMCs</b>	Peripheral blood mononuclear cells
<b>PCR</b>	Polymerase Chain Reaction
<b>PECAM-1</b>	Platelet Endothelial Cell Adhesion Molecule-1
<b>PET</b>	Preeclamptic toxemia
<b>PG I2</b>	Prostacyclin
<b>PISO</b>	Pregnancy-Induced Sympathetic Overactivity
<b>PIGF</b>	Placental growth factor
<b>POMP</b>	Polymorphic outer membrane proteins
<b>QID</b>	Latin: quater in die (=four times a day)
<b>RAS</b>	Renin-angiotensin system
<b>RBC</b>	Red Blood Cell
<b>RBs</b>	Reticulate bodies
<b>RDS</b>	Respiratory distress syndrome
<b>ReA</b>	Reactive arthritis
<b>RNA</b>	Ribonucleic acid
<b>ROS</b>	Reactive oxygen species
<b>SAP</b>	Stable Angina Pectoris
<b>sFlt-1</b>	soluble Fms-like tyrosine kinase
<b>TAFI</b>	Thrombin Activatable Fibrinolysis Inhibitor
<b>TAT</b>	Thrombin-Anti Thrombin III complex
<b>TFPI</b>	Tissue Factor Pathway Inhibitor
<b>TGF-B</b>	Transforming Growth Factor-B
<b>Th</b>	T-helper cell

## List of Abbreviations (Cont.)

<b>TIA</b>	Transient Ischaemic Attack
<b>TM</b>	Thrombomodulin
<b>TNF</b>	Tumor Necrosis Factor
<b>tPA</b>	Tissue-type Plasminogen Activator
<b>TRIA</b>	Time resolved fluoroscopic immunoassay
<b>TX A2</b>	Thromboxane A2
<b>VEGF</b>	Vascular Endothelial Growth Factor
<b>VWF</b>	von Willebrand factor
<b>WHO</b>	World Health Organization
<b>WIZARD</b>	Weekly Intervention with Zithromax for Atherosclerosis and its Related Disorders



## List of Tables

<b>Number</b>	<b>Title</b>	<b>Page</b>
Table(1):	Characteristics of the four Chlamydial species.	9
Table(2):	Basic properties of chlamydial bodies.	10
Table(3):	Suggested risk factors for pre eclampsia.	31
Table(4):	Seroprevalence of C. pneumoniae IgG among the 600 participating primigravidae.	86
Table(5):	The mean maternal age among C.pneumoniae IgG seronegative and C.pneumoniae IgG seropositive patients (years).	88
Table(6):	The body mass index among C.pneumoniae IgG seronegative and C.pneumoniae IgG seropositive patients (kg/m <sup>2</sup> ).	89
Table(7):	The rate of development of preeclampsia in C.pneumoniae IgG seropositive patients who received treatment (group T), C.pneumoniae IgG seropositive patients who did not receive treatment (group N) and the seronegative participants who remained seronegative at delivery (group 2).	91
Table(8):	Comparison between the rate of development of preeclampsia in C.pneumoniae IgG seropositive patients who received treatment (group T) and C.pneumoniae IgG seropositive patients who did not receive treatment (group N).	92

## List of Tables (cont.)

<b>Number</b>	<b>Title</b>	<b>Page</b>
Table(9):	Comparison between the rate of development of preeclampsia in C.pneumoniae IgG seropositive patients who received treatment (group T) and C.pneumoniae IgG seronegative patients who remained seronegative all through the pregnancy (no seroconversion occurred to them).	94
Table(10):	Comparison between the rate of development of preeclampsia in C.pneumoniae IgG seropositive patients who did not receive treatment (group N) and the seronegative patients who remained seronegative.	95
Table(11):	Severity of cases which developed preeclampsia among C.pneumoniae IgG seropositive patients who received treatment (group T) and who did not receive treatment (group N).	96
Table(12):	Clinical data of preeclamptic patients among C.pneumoniae IgG seropositive patients who received treatment (group T) and C.pneumoniae IgG seropositive patients who did not receive treatment (group N).	98
Table(13):	Gestational age at onset of preeclampsia among C.pneumoniae IgG seropositive patients who received treatment (group T) and who did not receive treatment (group N).	99

## List of Tables (cont.)

<b>Number</b>	<b>Title</b>	<b>Page</b>
Table(14):	Incidence of early (<34 wks) and late onset preeclampsia (> 34 wks)* among C.pneumoniae IgG seropositive patients who received treatment (group T) and who did not receive treatment (group N).	100
Table(15):	Gestational age at onset of preeclampsia among C.pneumoniae IgG seropositive patients who received treatment (group T) and who did not receive treatment (group N).	102
Table(16):	Incidence of preterm delivery (< 37 weeks of gestation) among C.pneumoniae IgG seropositive patients who received treatment (group T) and who did not receive treatment (group N).	103
Table(17):	Incidence of preterm delivery among preeclamptic and non-preeclamptic women in C.pneumoniae IgG seropositive patients who received treatment (group T) and who did not receive treatment (group N).	104
Table(18):	Comparison between the mode of delivery among C.pneumoniae IgG seropositive patients who received treatment (group T) and who did not receive treatment (group N).	106
Table(19):	Rate of cesarean section (CS) among preeclamptic and non-preeclamptic women in C.pneumoniae IgG seropositive patients who received treatment (group T) and who did not receive treatment (group N).	108

---

## List of Tables (cont.)

<b>Number</b>	<b>Title</b>	<b>Page</b>
Table(20):	Comparison between birth weight (kg) among C.pneumoniae IgG seropositive patients who received treatment (group T) and who did not receive treatment (group N).	110
Table(21):	Incidence of RDS among C.pneumoniae IgG seropositive patients who received treatment (group T) and who did not receive treatment (group N).	111
Table(22):	Incidence of RDS among preeclamptic and non-preeclamptic women in C.pneumoniae IgG seropositive patients who received treatment (group T) and who did not receive treatment (group N).	112
Table(23):	Perinatal loss among C.pneumoniae IgG seropositive patients who received treatment (group T) and who did not receive treatment (group N).	114
Table(24):	Comparison between preeclamptic and non-preeclamptic women in both studied groups as regards incidence of perinatal loss.	115

## List of Figures

<b>Number</b>	<b>Title</b>	<b>Page</b>
Figure(1):	Halberstaedter and Von Prowazek drawings of a normal conjunctival epithelial cell (left), an infected cell (center) and free chlamydial particles (right).	6
Figure (2)	The Chlamydia growth cycle.	11
Figure (3):	A diagram showing NO release from the vascular endothelium.	41
Figure (4):	Pathogenetic mechanisms through which C.pneumoniae could affect the development of atherosclerosis.	65
Figure (5):	Seroprevalence of C. pneumoniae IgG among 600 participating primigravidae.	87
Figure (6):	Drop out cases among C.pneumoniae IgG seropositive patients who received treatment (group T) and who did not receive treatment (group N).	90
Figure (7):	The rate of development of preeclampsia in C.pneumoniae IgG seropositive patients who received treatment (group T) and who did not receive treatment (group N).	93
Figure (8):	Severity of cases who developed preeclampsia among C.pneumoniae IgG seropositive patients who received treatment (group T) and who did not receive treatment (group N).	97
Figure (9):	Incidence of early (<34 wks) and late onset preeclampsia (> 34 wks) among C.pneumoniae IgG seropositive patients who received treatment (group T) and who did not receive treatment (group N).	101

## List of Figures (Cont.)

<b>Number</b>	<b>Title</b>	<b>Page</b>
Figure(10):	Incidence of preterm delivery among preeclamptic and non-preeclamptic women in C.pneumoniae IgG seropositive patients who received treatment (group T) and who did not receive treatment (group N).	105
Figure (11):	Comparison between C.pneumoniae IgG seropositive patients who received treatment (group T) and who did not receive treatment (group N) as regards mode of delivery.	107
Figure (12):	Rate of cesarean section (CS) among PET and non-PET women in C.pneumoniae IgG seropositive patients who received treatment (group T) and who did not receive treatment (group N).	109
Figure (13):	Distribution of RDS cases among C.pneumoniae IgG seropositive patients.	113

# دراسة نسبة إنتشار الأجسام المضادة للكلاميديا الرئوية بين السيدات الحوامل للمرة الأولى و تأثير علاج الكلاميديا على حدوث تسمم الحمل

رسالة مقدمة من

الطبيب/ عادل شفيق صلاح الدين

مدرس مساعد أمراض النساء والتوليد بمستشفيات جامعة عين شمس  
توطئة للحصول على درجة الدكتوراه في أمراض النساء والتوليد

تحت إشراف

الأستاذ الدكتور/ محمود علي أحمد الشوربجي

استاذ أمراض النساء والتوليد

كلية الطب - جامعة عين شمس

الأستاذ الدكتور/ محمد عبد الصبور الفرماوي

أستاذ الأمراض الصدرية

كلية الطب - جامعة عين شمس

الأستاذ الدكتور/ خالد كمال علي سيد

أستاذ أمراض النساء والتوليد

كلية الطب-جامعة عين شمس

الدكتور/ مها محمد فتحي

أستاذ مساعد أمراض الكائنات الدقيقة والمناعة

كلية الطب - جامعة عين شمس

الدكتور/ كريم أحمد حسن وهبه

مدرس أمراض النساء والتوليد

كلية الطب - جامعة عين شمس

جامعة عين شمس

2008

مقدمة